Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) – Analysts at Jefferies Financial Group dropped their FY2023 earnings per share (EPS) estimates for shares of Ultragenyx Pharmaceutical in a research note issued to investors on Sunday, November 3rd, Zacks Investment Research reports. Jefferies Financial Group analyst M. Raycroft now expects that the biopharmaceutical company will earn $5.07 per share for the year, down from their previous forecast of $5.20.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($1.96) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.71) by ($0.25). The business had revenue of $25.80 million for the quarter, compared to analyst estimates of $28.88 million. Ultragenyx Pharmaceutical had a negative return on equity of 52.16% and a negative net margin of 470.18%. The company’s revenue was up 119.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.74) earnings per share.
Several other research analysts have also weighed in on RARE. Leerink Swann reaffirmed a “positive” rating and issued a $85.00 target price (up from $80.00) on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, September 4th. Morgan Stanley dropped their target price on Ultragenyx Pharmaceutical from $79.00 to $76.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 6th. JPMorgan Chase & Co. reaffirmed a “buy” rating and set a $75.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, November 6th. BidaskClub upgraded Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Thursday, November 21st. Finally, Barclays reiterated a “buy” rating and set a $87.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Sunday, August 4th. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $73.33.
Shares of RARE stock traded up $0.45 during trading hours on Tuesday, reaching $39.30. 868,930 shares of the company’s stock were exchanged, compared to its average volume of 521,769. Ultragenyx Pharmaceutical has a 1 year low of $35.41 and a 1 year high of $74.50. The company’s 50 day moving average is $40.12 and its two-hundred day moving average is $51.92. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.79 and a quick ratio of 6.64. The company has a market cap of $2.25 billion, a P/E ratio of -5.32 and a beta of 2.15.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its position in Ultragenyx Pharmaceutical by 2.3% during the 2nd quarter. Vanguard Group Inc. now owns 5,005,872 shares of the biopharmaceutical company’s stock worth $317,874,000 after purchasing an additional 112,101 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in Ultragenyx Pharmaceutical by 31.7% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 4,611,939 shares of the biopharmaceutical company’s stock worth $292,858,000 after purchasing an additional 1,110,316 shares in the last quarter. Orbimed Advisors LLC grew its position in Ultragenyx Pharmaceutical by 948.0% during the 3rd quarter. Orbimed Advisors LLC now owns 834,313 shares of the biopharmaceutical company’s stock worth $35,692,000 after purchasing an additional 754,706 shares in the last quarter. Macquarie Group Ltd. grew its position in Ultragenyx Pharmaceutical by 19.6% during the 2nd quarter. Macquarie Group Ltd. now owns 797,293 shares of the biopharmaceutical company’s stock worth $50,628,000 after purchasing an additional 130,561 shares in the last quarter. Finally, Northern Trust Corp grew its position in Ultragenyx Pharmaceutical by 5.0% during the 2nd quarter. Northern Trust Corp now owns 691,110 shares of the biopharmaceutical company’s stock worth $43,886,000 after purchasing an additional 32,812 shares in the last quarter.
In related news, CEO Emil D. Kakkis purchased 5,000 shares of the company’s stock in a transaction on Wednesday, September 11th. The shares were bought at an average price of $43.63 per share, with a total value of $218,150.00. Following the completion of the acquisition, the chief executive officer now owns 472,479 shares of the company’s stock, valued at $20,614,258.77. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 7.80% of the stock is currently owned by corporate insiders.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.
Recommended Story: Forex
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ultragenyx Pharmaceutical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com’s FREE daily email newsletter.